Skip to main content

Want a detailed portfolio tracker?

Adaptive Biotechnologies (ADPT) Free Cash Flow (2018 - 2026)

Adaptive Biotechnologies (ADPT) free cash flow from Jun 30, 2018 to Mar 31, 2026. The TTM Adaptive Biotechnologies (ADPT) free cash flow is -$30M. You can adjust inflation or export chart.

All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.

Annual Free Cash Flow

Quarterly Free Cash Flow

Adaptive Biotechnologies (ADPT) Free Cash Flow CAGR table

PeriodCAGR
1 Year TTM-66.70%
3 Years TTM-46.67%
5 Years TTM-32.31%

Annual Free Cash Flow change of Adaptive Biotechnologies (ADPT)

YearFree Cash FlowChange
2026-$10M-78.88%
2025-$49M-50.49%
2024-$99M-40.80%
2023-$167M-16.61%
2022-$200M-21.29%
2021-$254M+51.04%
2020-$168M-186.76%
2019$194M-603.37%
2018-$39M+3.49%
2017-$37MN/A

Comparison Adaptive Biotechnologies (ADPT) five years free cash flow CAGR with competitors

Adaptive Biotechnologies (ADPT) five years free cash flow CAGR is -32.32%.

TickerNamefive years Free Cash Flow CAGRUpside
CDNACaredx Inc83.64%-358.78%
CRLCharles River Laboratories International Inc42.96%-232.93%
EXASExact Sciences Corp37.68%-216.57%
CSTLCastle Biosciences Inc24.94%-177.16%
MEDPMedpace Holdings Inc24.83%-176.83%
PSNLPersonalis Inc11.39%-135.24%
ICLRIcon Plc10.77%-133.31%
GHGuardant Health Inc10.63%-132.88%
IDXXIdexx Laboratories Inc10.21%-131.58%
RDNTRadnet Inc8.77%-127.12%
QGENQiagen NV6.88%-121.28%
MTDMettler-Toledo International Inc1.98%-106.12%
ILMNIllumina Inc1.82%-105.63%
IQVIQVIA Holdings Inc0.31%-100.95%